• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    A Vaccine Based on the Receptor-Binding Domain of the Spike Protein Expressed in Glycoengineered Pichia pastoris Targeting SARS-CoV-2 Stimulates Neutralizing and Protective Antibody Responses

    2022-08-17 01:51:04BoLiuYingYinYuxioLiuTintinWngPengSunYngqinOuXinGongXuchenHouJunZhngHonggungRenShiqingLuoQinKeYongmingYoJunjieXuJunWu
    Engineering 2022年6期

    Bo Liu, Ying Yin, Yuxio Liu, Tintin Wng, Peng Sun, Yngqin Ou, Xin Gong,Xuchen Hou, Jun Zhng, Honggung Ren, Shiqing Luo,e, Qin Ke,e, Yongming Yo*,Junjie Xu,*, Jun Wu,*

    a Department of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China

    b Medical Innovation Research Division & Fourth Medical Center of the Chinese PLA General Hospital, Beijing 100853, China

    c Department of Neurosurgery, First Medical Center of the Chinese PLA General Hospital, Beijing 100853, China

    d Shenzhen Taihe Biotechnology Co. Ltd., Shenzhen 518001, China

    e Institute of Physical Science and Information Technology, Anhui University, Hefei 230000, China

    Keywords:Coronavirus SARS-CoV-2 Vaccine Yeast Receptor-binding domain (RBD)

    ABSTRACT In 2020 and 2021, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus,caused a global pandemic. Vaccines are expected to reduce the pressure of prevention and control, and have become the most effective strategy to solve the pandemic crisis. SARS-CoV-2 infects the host by binding to the cellular receptor angiotensin converting enzyme 2(ACE2)via the receptor-binding domain(RBD)of the surface spike(S)glycoprotein.In this study,a candidate vaccine based on a RBD recombinant subunit was prepared by means of a novel glycoengineered yeast Pichia pastoris expression system with characteristics of glycosylation modification similar to those of mammalian cells. The candidate vaccine effectively stimulated mice to produce high-titer anti-RBD specific antibody. Furthermore, the specific antibody titer and virus-neutralizing antibody (NAb) titer induced by the vaccine were increased significantly by the combination of the double adjuvants Al(OH)3 and CpG. Our results showed that the virus-NAb lasted for more than six months in mice. To summarize, we have obtained a SARS-CoV-2 vaccine based on the RBD of the S glycoprotein expressed in glycoengineered Pichia pastoris,which stimulates neutralizing and protective antibody responses. A technical route for fucose-free complex-type N-glycosylation modified recombinant subunit vaccine preparation has been established.

    1. Introduction

    The global pandemic caused by the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has resulted in the infection of more than 99 million people and the deaths of 2.13 million people worldwide until 25 January 2021 [1]. SARS-CoV-2 binds to the host angiotensin converting enzyme 2 (ACE2) receptor via the receptor-binding domain (RBD) region of the spike (S) protein[2]. A change in the conformation of the S protein triggers membrane fusion,permitting virus invasion into cells.Studies have shown that RBD-specific antibodies can bind to either the upstream or downstream conformation of the RBD or to structures other than the ACE2 binding site, thereby blocking the binding of the RBD to ACE2 [3]; this makes the RBD an ideal antigen for neo-coronavirus vaccines[4,5].In vaccine design,therefore,inducing the immune system to produce antibodies against the RBD region in the S glycoprotein may be effective in preventing virus infection.

    The RBD contains two glycosylation sites,N331 and N343[6].At present, vaccines directed to the S protein or the RBD protein as antigens are produced by insect cells or mammalian cells [4,5].The production cycles of these two vaccine platforms are relatively long and have a relatively high cost. Yeast is an ideal proteinpreparation platform,as it is characterized by fast growth,low production cost,and rapid production[7].Yeast also has the ability of protein post-translational modifications, such as N-glycosylation[8]. However, N-glycosylation in yeast leads to hypermannosylation, which will cause protein epitope masking and high-level structural changes, thus affecting the immunogenicity and protective effect of the vaccine. Glycosylation engineering has led to the production of glycoengineered Pichia pastoris yeast,which performs glycosylation similar to that of mammalian cells while retaining the advantages of fast growth, low cost, and rapid reaction [9,10]. The H7N9 hemagglutinin glycoprotein vaccine expressed by glycoengineered yeast has been shown to have good immunogenicity and protective effects [11].

    Over the course of transmission, the virus continues to mutate,and these mutations confer various advantages. For example, the D614G mutation of the S glycoprotein increases the infectivity of the virus, and the N493K mutation in the RBD domain enhances the affinity of the RBD with the host ACE2 receptor by adding a pair of salt bridges [12]. The N493K mutation also reduces the binding capacity of the RBD with several monoclonal antibodies(including REGN10933, REGN10987, LY-CoV555, and s309, which are in clinical trials),thus enabling immune escape.An effective and safe vaccine is the most promising means of preventing the spread of the virus. The glycoengineered yeast expression system will be chosen to develop vaccines based on mutants of the virus S glycoproteins, as it is an industrial-scale system that can produce the candidate vaccines.

    In this study,the RBD glycoprotein of SARS-CoV-2 was expressed in glycoengineered yeast,and the administration of the RBD assisted by the aluminum hydroxide(Al(OH)3) and CpG adjuvants induced the production of virus-neutralizing antibody(NAb)in mice.

    Adjuvants are parts of vaccines that are used to enhance the magnitude, breadth, and durability of the immune response. At present, aluminum adjuvants are the most widely used adjuvants.Their wide application benefits from their effectiveness in a variety of vaccines, better safety (with only slight side effects), and lower price. Two types of aluminum adjuvants are commonly used in licensed vaccines: aluminum hydroxide adjuvant (AH) and aluminum phosphate adjuvant (AP) [13]. Although aluminum adjuvants have been used for many years, their immuneenhancement mechanism has not been fully explained. At present, the most recognized immune-enhancement mechanism of aluminum adjuvants is the‘‘depot effect”that involves the slow release of antigens from the site of immunization. Aluminum adjuvants tend to stimulate a T helper cell 2 (Th2) immune response. CpG oligodeoxynucleotides (ODNs) are a new type of vaccine adjuvant. They are ligands for Toll-like receptor 9 (TLR9),and can induce a T helper cell 1 (Th1) immune response. Three major classes of stimulatory CpG ODNs have been identified based on their structural characteristics and their activity on human peripheral blood mononuclear cells (PBMCs)—particularly on B cells and plasmacytoid dendritic cells (pDCs) [14]. CpG1018 is a CpG-B class oligonucleotide adjuvant that is currently being evaluated in clinical trials as a potential vaccine adjuvant for coronavirus disease 2019 (COVID-19) vaccines. The CpG-based hepatitis B virus (HBV) vaccine Heplisav-B, which is an improved HBV vaccine licensed for use in adults(age>18 years),offers a simplified two-dose regimen compared with other HBV vaccines[15].

    2. Material and methods

    2.1. Yeast strain, bacterial strain, plasmids, and materials

    The glycoengineered Pichia pastoris was reconstructed according to a previously reported method [16], which has also been described in our previous work [11]. The bacterial strain was cultured in Luria–Bertani (LB) medium containing 1.5% agar. The Escherichia coli DH5α (TakaRa Biotech, China) used for cloning was cultured at 37°C. Yeast extract, agar, and tryptone were purchased from OXOID (UK); a yeast nitrogen base without amino acids was obtained from Difco (USA); fetal bovine serum (FBS)was obtained from Beijing Qianzhao Xinye Biology Science and Technology Co., Ltd. (China); and T4 DNA ligase, restriction endonuclease, DNA ladder, Q5 DNA polymerase, and a molecular weight protein marker were obtained from New England Biolabs(USA). Anti-SARS-CoV RBD antibody and horseradish peroxidase(HRP)-goat anti-rabbit immunoglobulin G (IgG) antibody were obtained from Sino Biological (China). The DNA extraction kit and yeast genomic DNA kit were purchased from Sigma (USA).

    2.2. Cloning and expression of the SARS-CoV-2 RBD

    The SARS-CoV-2 RBD gene (GenBank accession number MN908947.3) was codon-optimized and synthesized by Tsingke(China). The RBD gene was cloned into the XhoI and NotI sites in the pPICZαA vector(Invitrogen,USA)to yield pPICZαA-RBD,which is driven by the AOX I promoter. The plasmid pPICZαA-RBD linearized with BglII was transformed into glycoengineered yeast by means of electroporation, and the resulting yeast was designated as Glycoeng-yeast/RBD. The Glycoeng-yeast/RBD clones were screened by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot using the anti-SARS-CoV RBD antibody and the HRP goat anti-rabbit IgG antibody(dilution ratio of 1:2500).

    2.3. Yeast fermentation and the RBD purification procedure

    Fermentations in 50 L bioreactors were conducted according to the methods described earlier [17]. In brief, the seed culture contained 200 mL of seed culture in yeast extract–peptone–dextrose(YPD) media. The fermentation culture contained 10 g yeast extract, 20 g peptone, 40 g glycerol, 4×10–3g biotin, 4.47 g Na2HPO4, 8.22 g NaH2PO4, and 13.4 g yeast nitrogen base (YNB)per liter of culture medium. The fermentations were carried out using the following conditions: The pH was controlled to 6.4 with NH4OH and the temperature was set at 25°C. After a 10 min starvation phase, the methanol feed (100% methanol with 12 mL?L–1Pichia trace minerals (PTM1) salts) was initiated.Methanol induction was continued for 45–50 h.

    The fermentation supernatant was recovered by centrifugation at 8000 revolutions per minute(rpm)for 25 min and then collected for RBD purification.The samples were sequentially subjected to a multimodal weak cation exchange (Capto MMC; GE Healthcare,USA), hydrophobic chromatography (Phenyl Sepharose High Performance; GE Healthcare, USA), strong anion exchange (Source 30Q; GE Healthcare, USA), strong cation exchange (Source 30S;GE Healthcare, USA), and size-exclusion chromatography (SEC;Superdex-200; GE Healthcare, USA) to finally obtain high-purity RBD protein.

    2.4. Characterization of SARS-CoV-2 RBD

    The purified recombinant RBD was analyzed using 12% SDSPAGE and treated with peptide-N-asparagine amidase (PNGase) F at 37°C. The purity of the RBD was analyzed by means of SEC–high-performance liquid chromatography (SEC–HPLC) and reverse-phase-high-performance liquid chromatography (RPHPLC). Absorbance values were recorded at 280 nm (Agilent 1260 HPLC).The recombinant RBD was analyzed using C8 RP-HPLC with a gradient of 0–100% mobile phase B over 40 min. Mobile phase A was composed of 0.1% formic acid (FA), and mobile phase B was composed of 95% acetonitrile and 0.1% FA.

    The binding capacity of the RBD produced from yeast cells and that produced from mammalian cells to human ACE2 was measured via enzyme-linked immunosorbent assay (ELISA). The solution of ACE2 was placed in a flat-bottomed 96-well plate at a final concentration of 10 μg?mL-1, coated with buffer(50 mmol?L–1carbonate, pH 9.6), and left at 4°C overnight. The plate was washed four times with a blocking solution of phosphate-buffered saline containing 0.1% Tween-20 (poly(butylene succinate-co-butylene terephthalate) (PBST)). Next, blocking solution in PBST containing 5% skim milk was added to the plate,which was then incubated for 1 h at 37°C. Serially diluted recombinant RBD was added,incubated at 37°C for 1 h,and then washed four times. The anti-SARS-CoV-2 RBD antibody was diluted by 1:2000 and added to the wells. After being incubated at 37°C for 1 h, the plates were washed four times. The goat anti-rabbit IgG horseradish peroxidase (HRP) binding antibody was diluted 1:2000 and added to the wells. After being incubated at 37°C for 1 h, the plates were washed four times and then developed with 3,3′,5,5′-tetramethylbenzidine for 15 min. 2 mol?L–1H2SO4stop solution at 50 μL per well was added to stop the reaction.

    2.5. Glycoform analysis experiment

    The DNA sequencer-assisted–fluorophore-assisted carbohydrate electrophoresis (DSA–FACE) method described previously[15]was used to detect oligosaccharide chains on the RBD.In brief,the glycoprotein was treated by glucosidase, and the sugar chains were marked with the fluorescent marker 8-aminopyrene-1,3,6-trisulfonic acid (APTS). The samples were separated under an ABI 3100 DNA sequencer (USA).

    2.6. Mice and vaccinations

    BALB/c mice were obtained from Beijing Weitong Lihua Laboratory Animal Technology Co.,Ltd.and raised at the Animal Center of the Beijing Institute of Biotechnology.All animal experiments were approved by the Institutional Animal Care and Use Committee of the Beijing Institute of Biotechnology and conducted in accordance with the institutional guidelines of the committee.The experimental animal welfare ethics number is IACUC-DWZX-2020-039.

    Female BALB/c mice aged 6–8 weeks were randomly divided into three groups(n=10)as the first batch of animal experiments:the 10 μg RBD/100 μg aluminum hydroxide(CRODA,Denmark)gel group; the 10 μg RBD/100 μg aluminum hydroxide gel/25 μg CpG group; and the phosphate-buffered saline (PBS) control group.Mice were immunized with 100 μL (intramuscular injection) in their hind leg muscles on days 0, 14, and 28.

    To determine the optimal immune dose of the RBD, 6–8 weekold BALB/c female mice were randomly divided into four groups(n=5) as the second batch of animal experiments: the 10 μg RBD/50 μg aluminum hydroxide gel/25 μg CpG group; the 5 μg RBD/50 μg aluminum hydroxide gel/25 μg CpG group; the 2.5 μg RBD/50 μg aluminum hydroxide gel/25 μg CpG group; and the PBS control group. Mice were immunized with 100 μL (intramuscular injection) in their hind leg muscles on days 0 and 14. To determine the best immunization strategy, we immunized the BALB/c mice at different times (n=5) as the third batch of animal experiments: two immunizations at days 0 and 14, respectively;two immunizations at days 0 and 21,respectively;two immunizations at days 0 and 28, respectively; and three immunizations at days 0, 14, and 28, respectively. The mice were immunized with 100 μL of 10 μg RBD/50 μg aluminum hydroxide gel/25 μg CpG(intramuscular injection) in their hind leg muscles.

    2.7. Histology and immunohistochemistry

    The five animals of each group in the first batch of animal experiments were decapitated four weeks after the last vaccine injection. The organs, including the hearts, lungs, livers, and spleens, were collected and fixed with formaldehyde, embedded in paraffin, and cut into slices. These sections were stained with hematoxylin and eosin,observed with a light microscope,and analyzed for histology.

    2.8. Analysis of RBD-specific serum antibodies

    The five animals of each group in the first batch of animal experiments were bled on days 14,28,42,98,154,and 182(weeks 2,4,6,14,22,and 26).The animals of the second and third batches of animal experiments were bled two weeks after the first and last vaccination. After the blood had clotted for 1–2 h at room temperature, the samples were centrifuged at 5000 rpm at 4°C for 15 min. The upper serum was collected and stored at –20°C.The recombinant RBD was coated onto a flat-bottom 96-well plate at a final concentration of 2 μg?mL-1in coating buffer(50 mmol?L–1carbonate, pH 9.6), and then left at 4°C overnight. The plate was washed four times with PBST. Next, blocking solution in PBST containing 5% skim milk was added to the plate, which was then incubated for 1 h at 37°C. Serially diluted mouse serum was then added. The plate was incubated at 37°C for 1 h, and then washed four times. The goat anti-mouse IgG HRP binding antibody was diluted to 1:4000 and added to the wells. After being incubated at 37°C for 1 h, the plates were washed four times and developed with 3,3′,5,5′-tetramethylbenzidine for 15 min. 2 mol?L–1H2SO4stop solution at 50 μL per well was then added to stop the reaction.The absorbance was detected on a 450 nm microplate reader.

    2.9. SARS-CoV-2 neutralization assay

    A micro-neutralization assay was used to detect the neutralization activities of the immunized mice serum in the biosafety level 3(BSL-3) facility [16]. In brief, serially diluted sera were incubated with 100 50% tissue culture-infectious dose (TCID50) of the SARS-CoV-2 strain (IME-BJ01) at 37°C for 2 h. Thereafter, the virus-serum complexes were transferred to a monolayer of Vero E6 cells cultured in 96-well plates.The inoculated plates were then incubated for 72 h and stained with 0.05%crystal violet for 35 min.Optical density(OD)values were measured at 570 or 630 nm after the addition of the decolorization solution. The neutralization results were calculated using the Reed-Muench method in order to estimate the serum dilution (50% effective concentration(EC50)titer)required to obtain half of the maximum neutralization of the infection. Seropositivity was defined as a titer ≥16. The initial serum dilution (1:16) was set as the confidence limit of the assay.

    Neutralizing activities against the SARS-CoV-2 501Y.V2 and B.1.1.7 pseudoviruses in the immunized mice serum were tested.The EC50was defined as the serum dilution at which the relative light units (RLUs) were reduced by 50% compared with the virus control wells(virus+cells)after the subtraction of the background RLUs in the control groups with cells only.In brief,the pseudovirus was incubated with serial dilutions of the test samples (six dilutions in a three-fold step-wise manner) in duplicate for 1 h at 37°C, together with the virus control and cell control wells in sexaplicate.Freshly trypsinized cells were then added to each well.After 24 h of incubation in a 5%carbon dioxide(CO2)environment at 37°C, the luminescence was measured, as described in section on pseudovirus titration. The EC50values were calculated with nonlinear regression—that is, log (inhibitor) versus response (four parameters)—using GraphPad Prism 8 (GraphPad Software, Inc.,USA).

    3. Results

    3.1. Expression of SARS-CoV-2 RBD protein in glycoengineered Pichia pastoris

    The RBD of the S protein was prepared using the glycoengineered Pichia pastoris expression system, which has mammalian N-glycosylation modification capacity[12].The RBD gene sequence of SARS-CoV-2 encodes a glycoprotein of 223 amino acids(residues 319–541 of the S protein) with a theoretical molecular mass of 25 kilodalton (kDa) and two N-glycosylation sites (N331 and N343). A schematic of the S protein containing the RBD gene and the expression vector for the RBD gene are shown in Figs. 1(a)and (b), respectively. The RBD gene was cloned between the XhoI and NotI sites of the pPICZαA vector to generate pPICZαARBD (SARS-CoV-2) (Fig. 1(b)). The linearized pPICZαA-RBD was transformed into glycoengineered yeast, and the resultant yeast strain was designated as Glycoeng-yeast/RBD. The results from Western blot testing revealed that all of the examined Glycoengyeast/RBD clones had approximately 30 kDa bands (Fig. 1(c)). The observed band from the SDS-PAGE analysis was heterogeneous,but the observed molecular weight (30 kDa) was higher than the theoretical molecular mass of 25 kDa, which may be because of the glycosylation of RBD.

    3.2.Efficient purification of RBD from glycoengineered Pichia pastoris

    We established a 4 L scale yeast fermentation process,with the whole fermentation cycle lasting for five days (Fig. 2(a)). Because RBD carries an α-factor secretion signal peptide (Fig. 1(b)), the expressed RBD was secreted into the culture supernatant. SDSPAGE analysis of the supernatant from yeast induced at different time points showed that the expression level of the RBD was high after 48 h of induction(Fig.2(b)).The RBD secreted into the supernatant was obtained by means of a cation exchange column,hydrophobic chromatography,anion chromatography,cation chromatography, and gel filtration chromatography. High-purity RBD protein was obtained with a yield of 50 mg?L–1.SDS-PAGE analysis confirmed that the purified RBD protein ran as a single band(Fig.2(c)). The RBD protein showed single, sharp SEC–HPLC (TSK gel G2000SWXL, 5 μm, φ 7.8 mm×300 mm) and RP–HPLC (Agilent ZORBAX 300SB-C8,5 μm,φ 4.6 mm×250 mm)profiles,indicating high purity and integrity (Fig. 2(d)). The binding capacity of the RBD produced from yeast cells and mammalian cells to human ACE2 was measured by ELISA. The absorbance was detected on a microplate reader of 450 nm. The results indicated no significant difference between the binding capacity of the RBD produced from yeast cells and that produced from mammalian cells to human ACE2 (P=0.5784) (Fig. 2(e)).

    3.3. Purified RBD shows complex glycosylated modifications

    The apparent molecular mass of the purified RBD protein(approximately 30 kDa)was about 25%greater than the theoretical molecular mass (approximately 25 kDa). The RBD protein treated with PNGase F was consistent with theoretical mass of 25 kDa (Fig. 3(a)), suggesting that the RBD had undergone N-glycosylation modification. The RBD expressed by glycoengineered yeast had a terminally biantennary galactosylated glycan,as analyzed by DSA–FACE (Fig. 3(b)). DSA–FACE was used to characterize the RBD N-glycans by using bovine ribonuclease B as a marker,and five kinds of glycans(Man5GlcNAc2to Man9GlcNAc2,or M5–M9) were identified (Fig. 3(b-I)) [18]. The glycans of the RBD expressed in yeast were incubated with β1-4-galactosidase, β-N-acetylglucosaminidase, and α1-2,3 mannosidase,respectively,or with a mixture of β1-4-galactosidase and β-N-acetylglucosaminidase. The β1-4-galactosidase removed the terminal galactoses on the N-glycan from Gal2GlcNAc2Man3-GlcNAc2, resulting in the generation of GlcNAc2Man3GlcNAc2(Fig. 3(b-IV)). The β-N-acetylglucosaminidase further cut the N-acetylglucosamine from the N-glycans to generate Man3GlcNAc2(Fig. 3(b-V). The α1-2,3 mannosidase was used to generate Man2GlcNAc2from Man5GlcNAc2(Fig. 3(b-VI)). Over all, the yeast-expressed RBD was modified at the afucosylated mannosetype and complex glycans characterized as Man5GlcNAc2and Gal2-GlcNAc2Man3GlcNAc2(Fig. 3(b-II)). In comparison, previous work on HEK293-derived and Chinese hamsters ovary cells-derived RBD has shown that they mainly possess fucosylated diantennary and triantennary complex-type N-glycans and have a small amount of high mannose N-glycans (Man5, Man6) with or without phosphorylation [19].

    Fig.1. Characterization and expression of the RBD protein of SARS-CoV-2.(a)Schematic of the SARS-CoV-2 S protein sequence,showing the N-terminal domain(NTD),RBD,heptad repeats 1 and 2 (HR1 and HR2), transmembrane domain (TM), subdomains 1 and 2 (SD1 and SD2), fusion peptide (FP), and transmembrane region (TM). Nglycosylation sites are marked with the residue numbers(331 and 343).(b)Map of the pPICZαA-RBD plasmid.(c)SDS-PAGE and Western blot analysis of various Glycoengyeast/RBD clones, shown in lanes 1, 2, 3, and 4. M: marker; CYC1: cytochrome C1; EM7: synthetic prokaryotic promoter that drives constitutive expression of the Zeocin resistance gene in Escherichia coli; TEF1: translation elongation factor 1; AOX1: aldehyde oxidase 1; BleoR: bleomyicin-R.

    Fig.2. Fermentation of yeast35/RBD and the RBD purification procedure.(a)The complete fermentation process of the RBD protein,showing the stirring speed(STIRR;black),dissolved oxygen(pO2;red),variations of temperature(TEMP;blue),base filling amount(BASE;dark green),pH(light green),and acid filling amount(ACID;purple).(b)SDSPAGE analysis of RBD expression at different culture times. (c) SDS-PAGE of the RBD during the purification process. (d) SEC–HPLC and RP–HPLC of the purified RBD.(e) Binding capacity to human ACE2 of RBD produced from yeast cells and RBD produced from mammalian cells. Phenyl HP: phenyl sepharose high performance;G25 fine:Sephadex G25 coarse; Superdex-200: Superdex-200 prep grade; OD450: optical density at 450 nm; AU: absorbance unit.

    Fig. 3. Characterization of the RBD. (a) SDS-PAGE results of RBD digested with PNGase F.(b)N-glycans analysis of the RBD protein:(I)Reference glycans of bovine RNase B (Man5GlcNAc2–Man9GlcNAc2); (II) N-glycans of RBD protein; (III) glycans of RBD digested with β-N-acetylglucosaminidase;(IV)glycans of RBD digested with β1-4-galactosidase; (V) glycans of RBD digested with β-N-acetylglucosaminidase and β1-4-galactosidase; (VI) glycans of RBD digested with α1-2,3 mannosidase.PNGF: peptide-N-glycosidase F; RFU: relative fluorescence unit.

    3.4. Identification of antibodies against RBD

    To develop vaccines using the RBD, we selected aluminum hydroxide as the adjuvant for its safety and effectiveness. To prepare the vaccine, aluminum hydroxide was added to the RBD,resulting in precipitation of the candidate vaccine with aluminum gel.To evaluate the potential of the RBD as a vaccine,the RBD was given to BALB/c mice with CpG (CpG2006) [13,20] and aluminum hydroxide as double adjuvants. PBS was given as the control. At 14 days after the last immunization, serum samples were collected.

    The RBD immunogen with the combination of CpG and aluminum hydroxide as the adjuvants markedly increased the immunogenicity of the antibody titer (Fig. 4(a)). At 14 days after the first immunization, the specific antibody titers of the RBD+Al(OH)3+CpG group and the RBD+Al(OH)3group were 7.4×104and 66.0, respectively (P<0.0001). At 14 days after the second immunization,the antibody titer of the RBD+Al(OH)3+CpG group was 6.8×106and that of the RBD+Al(OH)3group was 7.9×103. The RBD+Al(OH)3+CpG group induced a significantly higher antigen-specific IgG compared with the RBD+Al(OH)3group(P<0.0001). Because of the low antibody titer in the RBD+Al(OH)3group, a third immunization was performed. Two weeks later, the antibody titer of the RBD+Al(OH)3group was 3.4×105,but that of the RBD+Al(OH)3+CpG group(i.e.,four weeks after the second immunization) without the third immunization was approximately 4.5×106(P<0.0001). These results indicated that the RBD with both CpG and aluminum hydroxide was superior to the RBD with the aluminum hydroxide adjuvant as an immunogen.

    We next tested sera from the groups for neutralizing activities against live SARS-CoV-2 virus (IME-BJ01) (Fig. 4(b)). At 14 days after the first immunization, the titers of NAb in the RBD+Al(OH)3+CpG group and the RBD+Al(OH)3group were below 1:16, which was basically the same as that in the negative control group. At 14 days after the second immunization, the NAb titer of the RBD+Al(OH)3group was still below 1:16, but that of the RBD+Al(OH)3+CpG group was 1:1000 (ranging from 430 to 2800). The RBD+Al(OH)3+CpG group elicited higher titers of NAb compared with the RBD+Al(OH)3group(P<0.05).At 14 days after the third immunization, the NAb titer was 1:105 (ranging from 33 to 210) in the RBD+Al(OH)3group; the NAb titer in the RBD+Al(OH)3+CpG group without the third immunization (four weeks after the second immunization) was 1:1259 (ranging from 310 to 1900) (P<0.05).

    To determine the optimal immunity dose of RBD,we performed the experiment with different doses of the RBD antigen.At 14 days after the first immunization, the antibody titers of the 10 μg RBD group and the 5 μg RBD group were 7.9×104and 5.0×104(P=0.1268) (Fig. 4(c)). The antibody titer of the 2.5 μg RBD group was 5.0×104, which was not significantly different from that of the 10 μg RBD group (P=0.1268). At 14 days after the second immunization, the antibody titers of the 10 μg RBD group and the 5 μg RBD group were 3.2×106and 2.5×106, respectively(P=0.3739). The antibody titer of the 2.5 μg RBD group was 1.0×106, and less antigen-specific IgG was induced compared with the 10 μg RBD group(P<0.05).These results indicated no significant difference in the antibody titer induced by 10 μg or 5 μg of RBD antigen immunization to BALB/c mice with 50 μg Al(OH)3and 25 μg CpG per dose; however, the immunity effect using 2.5 μg RBD was poor.

    Fig.4. Immunity effects of vaccines with different adjuvant components on BALB/c mice.(a)Antibody titers after three immunizations with vaccines with different adjuvant components; no third immunization was performed in the RBD+Al(OH)3+CpG group. (b) Antibody neutralizing activity of vaccines with different adjuvant components after three immunizations;no third immunization was performed in the RBD+Al(OH)3+CpG group.(c)Antibody titers of 100 μL vaccine preparations mixed with different doses of RBD (10.0, 5.0, and 2.5 μg), 50 μg of Al(OH)3 adjuvant and 25 μg of CpG for 14 days and 28 days after the first immunization. (d) Antibody titers at 14 days after immunization with the RBD vaccine with different immunization strategies(5 μg RBD mixed with 50 μg Al(OH)3 adjuvant and 25 μg CpG mixed in 100 μL).ns:no significant difference; NS: normal saline. P-values were analyzed with t tests; ns: p > 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001.

    To determine the best immunization strategy, we immunized BALB/c mice at different time: two immunizations at days 0 and 14; two immunizations at days 0 and 21; two immunizations at days 0 and 28; and three immunizations at days 0, 14, and 28. At 14 days after the first immunization, no significant difference was found in the antibody titer (Fig. 4(d)). At day 14 after the second immunization, the antibody titers were 4.0×106in the‘‘0,14 d”group and 3.2×106in the‘‘0,21 d”group.The titers were 5.0×106in the ‘‘0, 14, 28 d” group at 14 days after the third immunization and 2.0×106in the‘‘0,28 d”group at 14 days after the second immunization. The ‘‘0, 14, 28 d” group induced significantly more antigen-specific IgG compared with the ‘‘0,28 d”group.No significant difference was noted between the other groups.These results indicate that the‘‘0,14 d,”‘‘0,21 d,”or‘‘0,14,28 d” schedules could be potential immunization strategies.

    3.5. Safety evaluation

    To evaluate the toxicity of the RBD candidate vaccine,histopathological changes of the main organs including the liver,lung, and heart tissues were examined by light microscopy. The results revealed no obvious differences between the experimental and control groups (Fig. 5).

    3.6. Characterization of the persistence of RBD antibody response

    To determine the persistence of the antibody titer,blood samples were collected from the tails of mice at weeks 2,4,6,14,22,and 26 after immunization. The antibody titer of the RBD+Al(OH)3+CpG group was 6.3×106at 14 days and 3.2×106at 12 weeks after the second immunization (Fig. 6(a)) (P=0.0604).The antibody titer was 6.3×105at 22 weeks after immunization and 6.3×105after 26 weeks. The antibody titer of the RBD+Al(OH)3group was 3.2×105at two weeks after the third immunization and 6.3×105at 14 weeks after the immunization(P=0.1823).The antibody titer was 1.6×105at 22 weeks after the immunization,and there was no significant difference with the antibody titer 2 weeks after the third immunization (P=0.1878). At 26 weeks after immunization,the antibody titer was 2.5×104.

    Fig.5. Possible histopathological changes to organs including liver,lung,and heart tissues(stained by hematoxylin and eosin)were observed by means of light microscopy.

    To determine the persistence of the NAb titer, blood was collected at weeks 2, 4, 6, 14, 22, and 26 after the last immunization.The NAb titer of the RBD+Al(OH)3+CpG group was 1:1000(ranging from 430 to 2800)at four weeks after immunization and 1:501(ranging from 250 to 1500) at 26 weeks after immunization(P=0.2218) (Fig. 6(b)). The antibody titer of the RBD+Al(OH)3group was 1:105 (ranging from 33 to 210) at two weeks after the third immunization and 1:63 (ranging from 28 to 170) after 26 weeks (P=0.5545).

    At 14 days after the third immunization, the NAb titer of the RBD+Al(OH)3group against 501Y.V2 was 1:182, and that of the RBD+Al(OH)3+CpG group was 1:347. At 14 days after the third immunization, the NAb titer of the RBD+Al(OH)3group against B.1.1.7 was 1:832, and that of the RBD+Al(OH)3+CpG group was 1:1047. Thus, our data show that the vaccination determined cross-neutralization against B.1.1.7 and 501Y.V2 (Fig. 6(c)).

    4. Discussion

    Similar to the S proteins of other viruses,the S protein of SARSCoV-2 is coated with carbohydrate chains,which potentially mask epitopes to block the host’s immune response.The S protein monomer has 22 N-glycosylation sites[21],with two glycosylation sites,N331 and N343, in the RBD region. Correct glycosylation of antigens is critical for immunogenicity. Many vaccine technologies based on the S protein currently use mammalian cells or insect cells as the expression system in order to ensure the correct glycosylation modification. Yeast, a lower eukaryote, has the ability of hyper-mannosylation. Studies have shown that hypermannosylation modifications may mask the epitope of antigens[22]. The H7N9 influenza virus hemagglutinin (HA) subunit particle vaccine prepared by means of glycosylation-modified humanized yeast, which has mammalian N-glycosylation ability,has been shown to have good immunogenicity and protected mice from the H7N9 virus [11]. In this study, we used glycoengineered Pichia pastoris to express SARS-CoV-2 RBD. DSA–FACE analysis showed that the N-glycosyl groups in the RBD were a fucose-free complex glycosyl group and a low-mannose glycosyl group,which ensured that the RBD epitope could not be masked.

    To examine the safety of the candidate RBD vaccine, we examined the potential toxicity of the RBD vaccine in mice. No adverse effects were observed,such as body weight and behavioral changes(data not shown). There were no significant pathological changes in the liver, lung, heart, and other organs on microscopic examination.

    Fig. 6. Detection of RBD antibody persistence at 6 months after immunization.(a) Antibody titer persistence at 26 weeks after immunization with different adjuvant components. (b) Antibody neutralizing activity persistence at 26 weeks after immunization with different adjuvant components. (c) Neutralizing activities against the SARS-CoV-2 501Y.V2 and B.1.1.7 pseudoviruses. ED50:median effective dose. P-values were analyzed with t tests; ns: p > 0.05, ***: p < 0.001.

    In our study, we found that Al(OH)3combined with CpG had a significant adjuvant effect. In mice, Al(OH)3combined with CpG induced a strong humoral and cellular immune response against the RBD. During the 26-week follow-up, the titer of virus-NAb did not significantly decrease. These results provide immunogenicity research data for a vaccine using RBD expressed by glycoengineered yeast as the immunogen.Importantly,the glycoengineered yeast production platform can quickly respond to virus mutations with an expandable production scale.Thus,the preparation of candidate vaccines can be expected to be completed with a stable production process within a few weeks. The candidate RBD vaccine presented here has the potential to contribute significantly to the control of the COVID-19 pandemic.If the SARS-CoV-2 subunit vaccine with the CpG and Al(OH)3adjuvants proves to be successful,rapid production of viral glycoproteins based on glycoengineered yeast will become an important new technology for rapid response to any emerging viral threat.

    Acknowledgments

    This work was supported by the National Key Research and Development Program of China (2020YFC0841400-008), the NationalScienceandTechnologyMajorProjects(2018ZX09711003-013-002), and the National Natural Science Foundation of China (81673339 and 81773619).

    Compliance with ethics guidelines

    Bo Liu, Ying Yin, Yuxiao Liu, Tiantian Wang, Peng Sun, Yangqin Ou, Xin Gong, Xuchen Hou, Jun Zhang, Hongguang Ren, Shiqiang Luo, Qian Ke, Yongming Yao, Junjie Xu, and Jun Wu declare that they have no conflict of interest or financial conflicts to disclose.

    一个人看视频在线观看www免费| 国产真实乱freesex| 观看美女的网站| 一本久久中文字幕| 成人二区视频| 国产激情偷乱视频一区二区| 一进一出抽搐gif免费好疼| 菩萨蛮人人尽说江南好唐韦庄 | 麻豆国产97在线/欧美| 亚洲七黄色美女视频| 三级毛片av免费| 国产 一区 欧美 日韩| 黄色配什么色好看| 在线观看av片永久免费下载| 国产精品国产三级国产av玫瑰| 女人十人毛片免费观看3o分钟| av女优亚洲男人天堂| 在线播放国产精品三级| 欧美最新免费一区二区三区| 菩萨蛮人人尽说江南好唐韦庄 | 性色avwww在线观看| 欧美成人精品欧美一级黄| 午夜免费男女啪啪视频观看| 日本免费一区二区三区高清不卡| 色哟哟·www| 在线观看午夜福利视频| 欧美极品一区二区三区四区| 色综合色国产| 精品人妻视频免费看| 国产精品爽爽va在线观看网站| 日本欧美国产在线视频| 男女那种视频在线观看| 波多野结衣巨乳人妻| 国产色婷婷99| 日韩视频在线欧美| 内地一区二区视频在线| 国产老妇伦熟女老妇高清| 午夜老司机福利剧场| 一本久久精品| 精品人妻熟女av久视频| 午夜激情福利司机影院| 男人狂女人下面高潮的视频| 99在线视频只有这里精品首页| 成人二区视频| 又爽又黄a免费视频| 国产成人a区在线观看| 97超碰精品成人国产| 亚洲欧美成人精品一区二区| 免费看光身美女| www.av在线官网国产| 女同久久另类99精品国产91| 国内少妇人妻偷人精品xxx网站| 亚洲精品成人久久久久久| 久久中文看片网| 看片在线看免费视频| 六月丁香七月| 99久国产av精品国产电影| 女的被弄到高潮叫床怎么办| 久久精品国产亚洲av天美| 亚洲无线观看免费| 日本黄色视频三级网站网址| 蜜臀久久99精品久久宅男| 99热网站在线观看| 久久精品综合一区二区三区| 我要搜黄色片| 最后的刺客免费高清国语| 毛片一级片免费看久久久久| 插阴视频在线观看视频| 国产日本99.免费观看| 亚洲不卡免费看| 联通29元200g的流量卡| 在线播放无遮挡| 伊人久久精品亚洲午夜| 黄色日韩在线| 男的添女的下面高潮视频| av天堂在线播放| 色综合亚洲欧美另类图片| 变态另类丝袜制服| 天美传媒精品一区二区| 最近手机中文字幕大全| 国产大屁股一区二区在线视频| 欧美日韩综合久久久久久| 久久久成人免费电影| 性插视频无遮挡在线免费观看| 精品久久久久久成人av| 亚洲电影在线观看av| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 国产v大片淫在线免费观看| 国产免费男女视频| 国产一区二区在线观看日韩| 插阴视频在线观看视频| 久久久精品大字幕| 国产爱豆传媒在线观看| 久久综合国产亚洲精品| 欧美高清性xxxxhd video| 久久久久久久久久久免费av| 日韩欧美三级三区| 久久精品夜色国产| 亚洲欧美日韩东京热| 男女下面进入的视频免费午夜| 欧美zozozo另类| 国产v大片淫在线免费观看| www.av在线官网国产| 国产精品av视频在线免费观看| 日韩欧美精品免费久久| 99精品在免费线老司机午夜| 中文欧美无线码| 欧美日韩乱码在线| 丝袜喷水一区| 身体一侧抽搐| 欧美性感艳星| 亚洲精品456在线播放app| 成人高潮视频无遮挡免费网站| 久久精品夜夜夜夜夜久久蜜豆| 一个人观看的视频www高清免费观看| 高清毛片免费看| 变态另类成人亚洲欧美熟女| 五月玫瑰六月丁香| 久久精品久久久久久久性| 99久久精品一区二区三区| 天天一区二区日本电影三级| 此物有八面人人有两片| 亚洲18禁久久av| 久久久精品欧美日韩精品| 久久韩国三级中文字幕| 久久精品久久久久久久性| 十八禁国产超污无遮挡网站| 免费av不卡在线播放| 男的添女的下面高潮视频| 26uuu在线亚洲综合色| 国产一区二区激情短视频| 丝袜美腿在线中文| 麻豆av噜噜一区二区三区| 老师上课跳d突然被开到最大视频| 久久久欧美国产精品| 成人亚洲欧美一区二区av| 久久欧美精品欧美久久欧美| 国产伦精品一区二区三区视频9| 精品久久国产蜜桃| 99在线视频只有这里精品首页| 97超碰精品成人国产| 看非洲黑人一级黄片| 久久午夜福利片| 男女那种视频在线观看| 欧美又色又爽又黄视频| 日韩高清综合在线| kizo精华| 男人舔女人下体高潮全视频| 国产精品一区www在线观看| kizo精华| 亚州av有码| 国产美女午夜福利| 欧美不卡视频在线免费观看| 99在线人妻在线中文字幕| 久久精品国产亚洲网站| 欧美区成人在线视频| 国产国拍精品亚洲av在线观看| 国产精品一二三区在线看| 黄色日韩在线| 一级二级三级毛片免费看| 欧美极品一区二区三区四区| 国产一级毛片七仙女欲春2| 一级毛片电影观看 | 一本精品99久久精品77| 自拍偷自拍亚洲精品老妇| 91久久精品国产一区二区成人| 老师上课跳d突然被开到最大视频| 大型黄色视频在线免费观看| 亚洲五月天丁香| 欧美一级a爱片免费观看看| 日产精品乱码卡一卡2卡三| 狠狠狠狠99中文字幕| 99热这里只有精品一区| 国产极品天堂在线| 嫩草影院精品99| 狂野欧美白嫩少妇大欣赏| av专区在线播放| 如何舔出高潮| 亚洲美女搞黄在线观看| 青春草视频在线免费观看| 亚洲国产精品国产精品| 日韩欧美在线乱码| 日本黄大片高清| 日韩精品青青久久久久久| 国产精品福利在线免费观看| 国产av不卡久久| 我要看日韩黄色一级片| 性色avwww在线观看| 日本一本二区三区精品| 成年女人看的毛片在线观看| 精品人妻视频免费看| 听说在线观看完整版免费高清| 在现免费观看毛片| 亚洲天堂国产精品一区在线| 两性午夜刺激爽爽歪歪视频在线观看| 日本免费一区二区三区高清不卡| 黑人高潮一二区| 国产精品久久视频播放| 蜜桃亚洲精品一区二区三区| 国产成人一区二区在线| 久久99精品国语久久久| 国产精品日韩av在线免费观看| 久久草成人影院| 欧美日韩一区二区视频在线观看视频在线 | 国产三级中文精品| 天天躁日日操中文字幕| 在线国产一区二区在线| 久久久久久伊人网av| 久久久久性生活片| 变态另类成人亚洲欧美熟女| 噜噜噜噜噜久久久久久91| 一卡2卡三卡四卡精品乱码亚洲| 国产女主播在线喷水免费视频网站 | 国产亚洲5aaaaa淫片| 亚洲婷婷狠狠爱综合网| 国产伦一二天堂av在线观看| 精品午夜福利在线看| 欧美丝袜亚洲另类| 天堂中文最新版在线下载 | 天堂av国产一区二区熟女人妻| av免费观看日本| 国内精品宾馆在线| 免费无遮挡裸体视频| 亚洲精品粉嫩美女一区| 亚洲天堂国产精品一区在线| 欧美bdsm另类| 国产69精品久久久久777片| 亚洲人成网站在线播放欧美日韩| 日韩av在线大香蕉| 中国美白少妇内射xxxbb| 99热只有精品国产| 精品99又大又爽又粗少妇毛片| 12—13女人毛片做爰片一| 亚洲国产精品成人综合色| 国产av麻豆久久久久久久| 久久精品夜夜夜夜夜久久蜜豆| 国产美女午夜福利| 精品一区二区三区人妻视频| 亚洲高清免费不卡视频| 看免费成人av毛片| 一级毛片电影观看 | 免费av观看视频| 美女国产视频在线观看| 如何舔出高潮| 黄片无遮挡物在线观看| 51国产日韩欧美| av福利片在线观看| 亚洲aⅴ乱码一区二区在线播放| 精品久久久久久久人妻蜜臀av| 亚洲欧洲国产日韩| 晚上一个人看的免费电影| 日韩欧美 国产精品| 免费搜索国产男女视频| 欧美高清成人免费视频www| 亚洲一级一片aⅴ在线观看| 麻豆av噜噜一区二区三区| 我的老师免费观看完整版| 亚洲aⅴ乱码一区二区在线播放| 中文字幕av在线有码专区| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 麻豆成人av视频| 搡女人真爽免费视频火全软件| 好男人在线观看高清免费视频| 99精品在免费线老司机午夜| 我的女老师完整版在线观看| 久久久久久久久久久丰满| 国产精品无大码| 亚洲成人久久爱视频| av天堂中文字幕网| 99久久无色码亚洲精品果冻| 特级一级黄色大片| 久久久精品欧美日韩精品| 亚洲在线观看片| 男人舔女人下体高潮全视频| 如何舔出高潮| 日本色播在线视频| 干丝袜人妻中文字幕| 成人毛片60女人毛片免费| 午夜福利在线观看吧| 伊人久久精品亚洲午夜| 欧美日韩乱码在线| 欧美人与善性xxx| 国产成人福利小说| 久久久精品大字幕| 国产成年人精品一区二区| 欧美极品一区二区三区四区| 日韩中字成人| 婷婷色av中文字幕| 国产一区二区三区av在线 | 午夜a级毛片| 少妇熟女欧美另类| 中文字幕av成人在线电影| 99久久精品国产国产毛片| 色综合色国产| 69人妻影院| 成人午夜精彩视频在线观看| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 波多野结衣高清无吗| 免费观看的影片在线观看| 黄色一级大片看看| 日日摸夜夜添夜夜爱| 欧美日本视频| 久久久久久大精品| 久久这里有精品视频免费| 黑人高潮一二区| 高清在线视频一区二区三区 | 中文精品一卡2卡3卡4更新| 高清毛片免费看| 精华霜和精华液先用哪个| 99热6这里只有精品| 日韩欧美 国产精品| 免费观看的影片在线观看| av福利片在线观看| 在线观看午夜福利视频| 插逼视频在线观看| 日韩欧美精品免费久久| 在线a可以看的网站| 狠狠狠狠99中文字幕| 国产伦在线观看视频一区| 国产成人福利小说| 亚洲在线观看片| 色吧在线观看| 久久精品国产鲁丝片午夜精品| 亚洲国产精品sss在线观看| 久久精品国产亚洲网站| 久久99精品国语久久久| 亚洲天堂国产精品一区在线| 国产精品一及| 级片在线观看| 日日撸夜夜添| 十八禁国产超污无遮挡网站| 五月玫瑰六月丁香| av在线老鸭窝| 又粗又硬又长又爽又黄的视频 | 国产 一区精品| 午夜激情福利司机影院| 日产精品乱码卡一卡2卡三| 最近的中文字幕免费完整| 精品一区二区三区人妻视频| 国产精品久久久久久精品电影小说 | 欧美又色又爽又黄视频| 99热6这里只有精品| 日本免费一区二区三区高清不卡| 欧美xxxx性猛交bbbb| 国产免费一级a男人的天堂| 午夜免费激情av| 免费av不卡在线播放| 国产黄片视频在线免费观看| 久久久久免费精品人妻一区二区| 少妇裸体淫交视频免费看高清| 亚洲无线观看免费| 搡老妇女老女人老熟妇| 亚洲最大成人中文| 久久韩国三级中文字幕| 日本成人三级电影网站| 国产精华一区二区三区| 国产成人精品久久久久久| 亚洲va在线va天堂va国产| 人人妻人人澡人人爽人人夜夜 | 国产私拍福利视频在线观看| 国产综合懂色| 日韩三级伦理在线观看| 免费人成在线观看视频色| 九九久久精品国产亚洲av麻豆| 成人亚洲精品av一区二区| 国产真实伦视频高清在线观看| 免费看av在线观看网站| 只有这里有精品99| 女人被狂操c到高潮| 日韩欧美精品v在线| 桃色一区二区三区在线观看| 国产精品无大码| 国产一级毛片在线| 国产一区二区在线观看日韩| 色尼玛亚洲综合影院| 一区福利在线观看| 国产av一区在线观看免费| 美女国产视频在线观看| 天堂网av新在线| 久久精品影院6| 啦啦啦观看免费观看视频高清| 亚洲18禁久久av| 免费观看精品视频网站| a级毛片免费高清观看在线播放| 啦啦啦韩国在线观看视频| 亚洲av成人av| 久久久欧美国产精品| 久久久精品欧美日韩精品| 中文资源天堂在线| 校园人妻丝袜中文字幕| 一个人看的www免费观看视频| 18禁在线无遮挡免费观看视频| 黄色一级大片看看| 一级毛片我不卡| 99视频精品全部免费 在线| 春色校园在线视频观看| av在线蜜桃| 亚洲国产色片| 国产三级中文精品| 国产一级毛片在线| 国产精品av视频在线免费观看| 在线播放国产精品三级| 国产高清视频在线观看网站| 亚洲人成网站在线观看播放| 午夜亚洲福利在线播放| 亚洲av二区三区四区| 欧美成人a在线观看| 国产精品1区2区在线观看.| 久久午夜福利片| 日本黄色视频三级网站网址| 成人性生交大片免费视频hd| 午夜福利在线在线| 老司机福利观看| 久久婷婷人人爽人人干人人爱| 在线播放国产精品三级| 长腿黑丝高跟| 中国美白少妇内射xxxbb| 日本爱情动作片www.在线观看| 一个人看视频在线观看www免费| 91久久精品国产一区二区成人| 国产精品1区2区在线观看.| 亚洲欧美清纯卡通| 亚洲人成网站在线播放欧美日韩| 午夜爱爱视频在线播放| 国产av在哪里看| 国产v大片淫在线免费观看| 看非洲黑人一级黄片| 中文字幕免费在线视频6| 在线观看一区二区三区| 日本一本二区三区精品| 国产精品爽爽va在线观看网站| 欧美+日韩+精品| 卡戴珊不雅视频在线播放| 亚洲人成网站在线播放欧美日韩| 亚洲国产色片| 91aial.com中文字幕在线观看| 国产精品久久久久久久久免| 久久精品国产清高在天天线| 国产伦精品一区二区三区四那| 激情 狠狠 欧美| 国产精品99久久久久久久久| 欧美xxxx黑人xx丫x性爽| 日本成人三级电影网站| 欧美色视频一区免费| 悠悠久久av| 在线免费观看不下载黄p国产| 色播亚洲综合网| 黄色一级大片看看| 毛片女人毛片| 日韩人妻高清精品专区| 久久久国产成人精品二区| 国产高清激情床上av| 中文在线观看免费www的网站| 精品一区二区免费观看| 老司机福利观看| 国产精品福利在线免费观看| 搡女人真爽免费视频火全软件| 一区二区三区免费毛片| 日韩成人伦理影院| 丰满人妻一区二区三区视频av| 亚洲成人久久爱视频| 欧美成人免费av一区二区三区| 成人毛片a级毛片在线播放| 国产成人a∨麻豆精品| 国产成人午夜福利电影在线观看| 五月玫瑰六月丁香| 亚洲图色成人| 少妇被粗大猛烈的视频| 少妇人妻精品综合一区二区 | 2021天堂中文幕一二区在线观| 亚洲四区av| www.av在线官网国产| 99九九线精品视频在线观看视频| 免费一级毛片在线播放高清视频| 亚洲综合色惰| 久久精品国产亚洲av天美| 日本色播在线视频| 麻豆av噜噜一区二区三区| 自拍偷自拍亚洲精品老妇| 久久精品久久久久久久性| 深夜a级毛片| 日本撒尿小便嘘嘘汇集6| 97人妻精品一区二区三区麻豆| 九九爱精品视频在线观看| 亚洲av成人av| 欧美日韩国产亚洲二区| 97热精品久久久久久| 熟女电影av网| 亚洲成人久久爱视频| 亚洲精品成人久久久久久| 精品人妻一区二区三区麻豆| 欧美性猛交黑人性爽| 少妇熟女aⅴ在线视频| 一边摸一边抽搐一进一小说| 国产三级中文精品| 一卡2卡三卡四卡精品乱码亚洲| 五月玫瑰六月丁香| 国产成人一区二区在线| 久久久久九九精品影院| 简卡轻食公司| 中文字幕av成人在线电影| 99久国产av精品| 亚洲av免费在线观看| 99久久精品一区二区三区| 两个人视频免费观看高清| 久久精品91蜜桃| 桃色一区二区三区在线观看| 热99在线观看视频| 国产欧美日韩精品一区二区| 欧美激情在线99| 不卡一级毛片| 日本黄色片子视频| 婷婷六月久久综合丁香| 赤兔流量卡办理| 成人午夜高清在线视频| 亚洲一区二区三区色噜噜| 久久精品久久久久久久性| 丰满的人妻完整版| 亚洲在线自拍视频| 久久综合国产亚洲精品| 女同久久另类99精品国产91| 国产精品一区www在线观看| 97人妻精品一区二区三区麻豆| 国产大屁股一区二区在线视频| a级毛片a级免费在线| 国产精品一区二区在线观看99 | 少妇的逼好多水| 国产成人freesex在线| 亚洲精品国产av成人精品| 神马国产精品三级电影在线观看| 亚洲美女搞黄在线观看| 成人特级av手机在线观看| 免费看光身美女| 亚洲av免费高清在线观看| 免费看a级黄色片| 亚洲av不卡在线观看| 99在线人妻在线中文字幕| 亚洲在久久综合| 男插女下体视频免费在线播放| 欧美+亚洲+日韩+国产| 欧洲精品卡2卡3卡4卡5卡区| 精品久久久久久久久av| 亚洲欧美日韩东京热| 久久久久网色| av国产免费在线观看| 亚洲在线观看片| 观看美女的网站| 三级国产精品欧美在线观看| 欧美丝袜亚洲另类| 美女黄网站色视频| 尾随美女入室| 毛片女人毛片| 亚洲成人中文字幕在线播放| 国产日韩欧美在线精品| 亚洲七黄色美女视频| 身体一侧抽搐| 99热这里只有精品一区| 亚洲欧洲日产国产| 夫妻性生交免费视频一级片| 三级毛片av免费| 国产精品久久久久久精品电影| 久久亚洲国产成人精品v| 插阴视频在线观看视频| 精品人妻视频免费看| 亚洲人成网站高清观看| 青春草亚洲视频在线观看| 99视频精品全部免费 在线| 欧美丝袜亚洲另类| 国产成年人精品一区二区| 亚洲国产精品合色在线| 1024手机看黄色片| 亚洲精品成人久久久久久| 可以在线观看毛片的网站| 亚洲欧美日韩卡通动漫| 亚洲精品乱码久久久久久按摩| 国产乱人偷精品视频| 欧美一区二区亚洲| 寂寞人妻少妇视频99o| 成人亚洲精品av一区二区| 国产精品日韩av在线免费观看| 精品不卡国产一区二区三区| 在线免费观看不下载黄p国产| 国产私拍福利视频在线观看| 麻豆成人av视频| 久久久国产成人免费| www日本黄色视频网| 美女被艹到高潮喷水动态| 卡戴珊不雅视频在线播放| 国产三级中文精品| 国产高清三级在线| 69人妻影院| 久久精品人妻少妇| 老师上课跳d突然被开到最大视频| 日韩成人av中文字幕在线观看| 色哟哟哟哟哟哟| 晚上一个人看的免费电影| 97在线视频观看| 精品不卡国产一区二区三区| 成年免费大片在线观看| 一边亲一边摸免费视频| 白带黄色成豆腐渣| 桃色一区二区三区在线观看| 丰满人妻一区二区三区视频av| 看免费成人av毛片| 国产黄色视频一区二区在线观看 | 高清毛片免费观看视频网站| 国产精品无大码| 免费一级毛片在线播放高清视频| 亚洲婷婷狠狠爱综合网| 国产精品无大码| 欧美最黄视频在线播放免费| 成人无遮挡网站| 91aial.com中文字幕在线观看| 国产av麻豆久久久久久久| 国模一区二区三区四区视频|